Published on 16 Feb 2024 on Simply Wall St. via Yahoo Finance
Investors in Heron Therapeutics (NASDAQ:HRTX) from five years ago are still down 90%, even after 23%...
Heron Therapeutics, Inc. ( NASDAQ:HRTX ) shareholders will doubtless be very grateful to see the share price up 164% in the last quarter. But that doesn't change the fact that the returns over the last half decade have been stomach churning. Like a ship taking on water, the share price has sunk 90% in that time. While the recent increase might be a green shoot, we're certainly hesitant to rejoice. The important question is if the business itself justifies a higher share price in the long term. While a drop like that is definitely a body blow, money isn't as important as health and happiness.
While the last five years has been tough for Heron Therapeutics shareholders, this past week has shown signs of promise. So let's look at the longer term fundamentals and see if they've been the driver of the negative returns.
Check out our latest analysis for Heron Therapeutics